Pazopanib versus sunitinib in metastatic renal-cell carcinoma. - Wikidata - awgldk - TriplyDB

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

http://www.wikidata.org/entity/Q33409916

about

Immunobiology and immunotherapy in genitourinary malignancies Contemporary Treatment of Metastatic Renal Cell Carcinoma Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective Pazopanib in the management of advanced soft tissue sarcomas Recent advances in the management of renal cell carcinoma Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma Pazopanib in the treatment of advanced renal cell carcinoma Sequence of treatment in locally advanced and metastatic renal cell carcinoma Current management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in review Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer Evaluation and management of patients with heart disease and cancer: cardio-oncology Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma Sunitinib in the treatment of metastatic renal cell carcinoma Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience Medical treatment of renal cancer: new horizons Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity Renal cell carcinoma.Renal cell cancer: overview of the current therapeutic landscape.Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.Use of "Real-World" data to describe adverse events during the treatment of metastatic renal cell carcinoma in routine clinical practice.Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review.Brazilian data of renal cell carcinoma in a public university hospital Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors.The role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials.Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program.Sunitinib Induced Immune Thrombocytopenia.Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa?

P2860

Q26738668-FA8E49A3-40DD-4E70-A1B3-BADF0657FEBA Q26740594-637ECAE5-6185-4756-8C60-71F55BDABFF1 Q26744089-78B7A58B-0A82-466D-BD67-B3DEBC363162 Q26746205-4D1BE3A7-A8B2-4CD7-98EC-93DEFC86E850 Q26750609-5BE056F2-9010-423F-AB48-70128DE393F3 Q26766240-E9E04DEB-2F9B-40C2-A155-9F73936219E3 Q26770413-6B7BB728-D1E3-48D0-95CB-A8E5BACE6E26 Q26773653-A5D5CEFD-214B-46FE-9D8F-EAA82C6D18EF Q26774515-7C4588BC-752F-4D8B-8310-F3359CAEA8C5 Q26775769-20059F74-F998-4CAC-BA13-7C774B5AEC79 Q26781662-87141F88-3466-48D6-8EFD-87180B29B01C Q26786534-D9271F17-07A4-4BCB-8454-2994D453B592 Q26801279-3AC90032-0CAE-491F-9B76-443CA7E404DD Q26822790-688BBC8B-A1A5-461F-AB5A-4348D6D0F09F Q26851417-05C2ABD2-B596-47D8-937B-5CF392548070 Q26852704-448FDF5B-45D7-4373-9B4B-C616643B71B8 Q26998273-7D0301D3-672D-40D0-8072-327100D86582 Q28066747-80C8D74B-A3EA-490F-BA15-AC87721EA96C Q28072057-712764C8-3DEC-4241-8251-72284292286C Q28072166-512F23BA-4E26-418B-94BE-8EC057A895EC Q28073174-F16798AB-0B63-4D81-B261-0ED2F478C33E Q28080163-1E9A1B11-F5FE-477E-A681-9DF213A5A999 Q28081844-E1C6AE6E-12EE-43B0-95CD-7561676085AA Q29247916-6D54A49A-93B5-455F-8142-038CF189B287 Q30235364-11F0DE90-D562-4E8D-96EF-48D8E4951947 Q30248354-0FE2C2A6-606E-4CEE-8947-36BA438C234C Q30382892-D3B793AE-B9AD-4BBE-82EF-6884AF14706A Q30842235-D5F955F4-C8A5-42CA-A8F0-B228008BD358 Q31010355-885339F4-5667-432A-AFB6-C3C24D879B34 Q31089209-FF4B8393-4AD1-48C9-92F8-2614EB1BE5D0 Q31102468-6CA5B51C-C115-4EA4-AD67-5534938C2090 Q33412909-0A6DCA76-7C83-4C6E-BB16-88ABF66EFCC2 Q33415118-5F60DC31-C104-43A8-B34D-27DB99193B09 Q33415481-3C2C3F6E-E4CD-40AF-84E1-220AEFEB8E06 Q33428370-96D3FC05-C4FE-4CAA-AA96-D7FBD4AD88FF Q33430139-D727614A-41E7-4809-8195-8D2CDF45434C Q33430940-08037FED-B054-41EB-BBC0-8C0C198221F7 Q33433070-1262C7E3-17ED-46FD-A7E7-ABBB66EDD212 Q33439519-C73376C2-A0DE-406A-8AC6-5533AC06A612 Q33467424-63142C88-0ECA-4B41-AAA9-3D7F1E4520CD

P2860

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

http://www.wikidata.org/entity/Q33409916

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

@ast

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

@en

type

label

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

@ast

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

@en

prefLabel

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

@ast

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

@en

P1433

Q33409916-14C86819-22EA-48C8-A8F1-03B5D8F481EC

P1476

Q33409916-610BBA6B-0477-4CB7-B906-47F976A12A3A

P2093

Q33409916-0FA23C63-A83D-4E96-B72A-BBEDC57361AB

Q33409916-0FE00F45-71A1-4A9D-A46D-ADE953809A2F

Q33409916-11169B3F-1714-4A71-9DFA-8FF57604BAC6

Q33409916-1E8C1A20-7B6E-491C-8DE1-35D44E0B93E5

Q33409916-251A1ACA-D1A3-47E3-ABB2-FA26B18DEE8C

Q33409916-2C0CDF2C-F2DD-4E47-A3DB-23AFF350E70E

Q33409916-361F6F04-261B-49D4-B6F4-0ECCB3598420

Q33409916-4A06DCA9-174C-4A0B-9C4A-6D61FAC699F0

Q33409916-4E7CDBA7-BC3E-4902-864E-AEA8101E761A

Q33409916-5E2D41B2-EB6F-4848-B273-9A43AA660FB4

P304

Q33409916-361B62F7-DB0E-43B0-B3FB-12A84C8482DB

P31

Q33409916-EFEAA467-8A0C-480D-A0CF-42DD20377664

P356

Q33409916-9180B609-B7E4-4A60-B2DE-B0D42AC3C379

P407

Q33409916-3F4B27E0-8176-477B-90A9-BB25657D22FC

P433

Q33409916-41EB239B-1C07-4864-B50E-98C0618705D8

P478

Q33409916-6D4C295E-14CA-4989-9FD6-58297E6E21FA

P50

Q33409916-CFEF5C49-3927-442D-BDB3-7CB126A0BE5F

Q33409916-D3AE026B-C07F-41FB-99B6-A684E1B172D7

P577

Q33409916-1DAE7396-12B0-4579-ADB1-E8CD48D34E26

P698

Q33409916-9CAA7402-EA33-4284-8D64-216743B374F2

P356

P1433

The New England Journal of Medicine

P1476

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

@en

P2093

Cora N Sternberg

http://www.w3.org/2001/XMLSchema#string

Ekaterini Boleti

http://www.w3.org/2001/XMLSchema#string

Hirotsugu Uemura

http://www.w3.org/2001/XMLSchema#string

Jaime R Merchan

http://www.w3.org/2001/XMLSchema#string

James Reeves

http://www.w3.org/2001/XMLSchema#string

Jie Jin

http://www.w3.org/2001/XMLSchema#string

Jinwan Wang

http://www.w3.org/2001/XMLSchema#string

Jun Guo

http://www.w3.org/2001/XMLSchema#string

Kate Fife

http://www.w3.org/2001/XMLSchema#string

Keith Deen

http://www.w3.org/2001/XMLSchema#string

P304

722-731

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1303989

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23964934

http://www.w3.org/2001/XMLSchema#string